In Vitro antibacterial activity of panduratin a against enterococci clinical isolates

Yaya Rukayadi, Sunghwa Han, DongEun Yong, Jae-Kwan Hwang

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Panduratin A, a natural chalcone compound isolated from the rhizome of fingerroot (Boesenbergia rotunda (L.) MANSF. A). The antibacterial activity of panduratin A against clinical enterococci isolates was compared in terms of minimum inhibitory concentration (MIC) and minimal bactericidal concentration (MBC) to those of commonly used antimicrobials, according to the CLSI guidelines. Time-kill curves were constructed to assess the concentration between MIC and bactericidal activity of panduratin A at concentrations ranging from 0 × MIC to 4 × MIC. The activity of panduratin A against biofilm-producing enterococcal strains was also evaluated. The growth of all clinical enterococci isolates (n=23) were inhibited by panduratin A at a concentration of 2 μg/ml. Panduratin A was able to kill all clinical enterococci isolates with a MBC of 8 μg/ml. The time-kill curves demonstrated that the bactericidal endpoint for clinical enterococci was reached after 30 min of incubation at a panduratin A concentration of 4 × MIC. The growth of biofilm-producing enterococcal strains can be inhibited and eradicated by panduratin A at concentrations of ≤4 μg/ml and ≤16 μg/ml, respectively. The antibacterial activity of panduratin A against all clinical enterococci isolates was generally more potent than commonly used antimicrobials. Panduratin A has stronger activity against biofilm-producing enterococcal strains than daptomycin and linezolid. Panduratin A is an antimicrobial agent with high in vitro activity against clinical enterococci, including organisms resistant to other antimicrobials.

Original languageEnglish
Pages (from-to)1489-1493
Number of pages5
JournalBiological and Pharmaceutical Bulletin
Volume33
Issue number9
DOIs
Publication statusPublished - 2010 Oct 11

Fingerprint

Enterococcus
Microbial Sensitivity Tests
Biofilms
Linezolid
panduratin A
In Vitro Techniques
Zingiberaceae
Daptomycin
Chalcone
Rhizome
Growth
Anti-Infective Agents
Guidelines

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmaceutical Science

Cite this

@article{bc301dd4fb8f42de8c396a9576bea2ab,
title = "In Vitro antibacterial activity of panduratin a against enterococci clinical isolates",
abstract = "Panduratin A, a natural chalcone compound isolated from the rhizome of fingerroot (Boesenbergia rotunda (L.) MANSF. A). The antibacterial activity of panduratin A against clinical enterococci isolates was compared in terms of minimum inhibitory concentration (MIC) and minimal bactericidal concentration (MBC) to those of commonly used antimicrobials, according to the CLSI guidelines. Time-kill curves were constructed to assess the concentration between MIC and bactericidal activity of panduratin A at concentrations ranging from 0 × MIC to 4 × MIC. The activity of panduratin A against biofilm-producing enterococcal strains was also evaluated. The growth of all clinical enterococci isolates (n=23) were inhibited by panduratin A at a concentration of 2 μg/ml. Panduratin A was able to kill all clinical enterococci isolates with a MBC of 8 μg/ml. The time-kill curves demonstrated that the bactericidal endpoint for clinical enterococci was reached after 30 min of incubation at a panduratin A concentration of 4 × MIC. The growth of biofilm-producing enterococcal strains can be inhibited and eradicated by panduratin A at concentrations of ≤4 μg/ml and ≤16 μg/ml, respectively. The antibacterial activity of panduratin A against all clinical enterococci isolates was generally more potent than commonly used antimicrobials. Panduratin A has stronger activity against biofilm-producing enterococcal strains than daptomycin and linezolid. Panduratin A is an antimicrobial agent with high in vitro activity against clinical enterococci, including organisms resistant to other antimicrobials.",
author = "Yaya Rukayadi and Sunghwa Han and DongEun Yong and Jae-Kwan Hwang",
year = "2010",
month = "10",
day = "11",
doi = "10.1248/bpb.33.1489",
language = "English",
volume = "33",
pages = "1489--1493",
journal = "Biological and Pharmaceutical Bulletin",
issn = "0918-6158",
publisher = "Pharmaceutical Society of Japan",
number = "9",

}

In Vitro antibacterial activity of panduratin a against enterococci clinical isolates. / Rukayadi, Yaya; Han, Sunghwa; Yong, DongEun; Hwang, Jae-Kwan.

In: Biological and Pharmaceutical Bulletin, Vol. 33, No. 9, 11.10.2010, p. 1489-1493.

Research output: Contribution to journalArticle

TY - JOUR

T1 - In Vitro antibacterial activity of panduratin a against enterococci clinical isolates

AU - Rukayadi, Yaya

AU - Han, Sunghwa

AU - Yong, DongEun

AU - Hwang, Jae-Kwan

PY - 2010/10/11

Y1 - 2010/10/11

N2 - Panduratin A, a natural chalcone compound isolated from the rhizome of fingerroot (Boesenbergia rotunda (L.) MANSF. A). The antibacterial activity of panduratin A against clinical enterococci isolates was compared in terms of minimum inhibitory concentration (MIC) and minimal bactericidal concentration (MBC) to those of commonly used antimicrobials, according to the CLSI guidelines. Time-kill curves were constructed to assess the concentration between MIC and bactericidal activity of panduratin A at concentrations ranging from 0 × MIC to 4 × MIC. The activity of panduratin A against biofilm-producing enterococcal strains was also evaluated. The growth of all clinical enterococci isolates (n=23) were inhibited by panduratin A at a concentration of 2 μg/ml. Panduratin A was able to kill all clinical enterococci isolates with a MBC of 8 μg/ml. The time-kill curves demonstrated that the bactericidal endpoint for clinical enterococci was reached after 30 min of incubation at a panduratin A concentration of 4 × MIC. The growth of biofilm-producing enterococcal strains can be inhibited and eradicated by panduratin A at concentrations of ≤4 μg/ml and ≤16 μg/ml, respectively. The antibacterial activity of panduratin A against all clinical enterococci isolates was generally more potent than commonly used antimicrobials. Panduratin A has stronger activity against biofilm-producing enterococcal strains than daptomycin and linezolid. Panduratin A is an antimicrobial agent with high in vitro activity against clinical enterococci, including organisms resistant to other antimicrobials.

AB - Panduratin A, a natural chalcone compound isolated from the rhizome of fingerroot (Boesenbergia rotunda (L.) MANSF. A). The antibacterial activity of panduratin A against clinical enterococci isolates was compared in terms of minimum inhibitory concentration (MIC) and minimal bactericidal concentration (MBC) to those of commonly used antimicrobials, according to the CLSI guidelines. Time-kill curves were constructed to assess the concentration between MIC and bactericidal activity of panduratin A at concentrations ranging from 0 × MIC to 4 × MIC. The activity of panduratin A against biofilm-producing enterococcal strains was also evaluated. The growth of all clinical enterococci isolates (n=23) were inhibited by panduratin A at a concentration of 2 μg/ml. Panduratin A was able to kill all clinical enterococci isolates with a MBC of 8 μg/ml. The time-kill curves demonstrated that the bactericidal endpoint for clinical enterococci was reached after 30 min of incubation at a panduratin A concentration of 4 × MIC. The growth of biofilm-producing enterococcal strains can be inhibited and eradicated by panduratin A at concentrations of ≤4 μg/ml and ≤16 μg/ml, respectively. The antibacterial activity of panduratin A against all clinical enterococci isolates was generally more potent than commonly used antimicrobials. Panduratin A has stronger activity against biofilm-producing enterococcal strains than daptomycin and linezolid. Panduratin A is an antimicrobial agent with high in vitro activity against clinical enterococci, including organisms resistant to other antimicrobials.

UR - http://www.scopus.com/inward/record.url?scp=77957555872&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957555872&partnerID=8YFLogxK

U2 - 10.1248/bpb.33.1489

DO - 10.1248/bpb.33.1489

M3 - Article

VL - 33

SP - 1489

EP - 1493

JO - Biological and Pharmaceutical Bulletin

JF - Biological and Pharmaceutical Bulletin

SN - 0918-6158

IS - 9

ER -